MOTS-c

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA Type-C) is a 16-amino-acid peptide encoded within the mitochondrial genome's 12S ribosomal RNA region, discovered in 2015 by researchers at the University of Southern California. This mitochondrial-derived peptide functions as a signaling molecule that translocates to the cell nucleus during metabolic stress, where it regulates nuclear gene expression through AMPK-dependent mechanisms. Primary research has focused on its roles in metabolic regulation, exercise performance, aging, insulin resistance, obesity, cardiovascular health, and bone metabolism. MOTS-c levels naturally decline with age in plasma, though skeletal muscle expression may increase compensatorily. The peptide is not approved by the FDA or other regulatory agencies for clinical use and remains an investigational compound available only in research settings. It is prohibited by the World Anti-Doping Agency (WADA) under metabolic modulators. Currently, MOTS-c is only available through research suppliers and is not approved for human therapeutic use outside of clinical trials.

Metabolic Regulation

• Glucose metabolism enhancement: MOTS-c targets skeletal muscle to improve glucose uptake and metabolism by inhibiting the folate cycle and activating AMPK signaling pathways ^[1][4]
• Insulin sensitivity: Treatment with MOTS-c significantly improves insulin sensitivity and glucose tolerance in animal models, reducing insulin resistance in diet-induced obesity ^[1][13][14]
• Obesity prevention: MOTS-c administration prevents high-fat diet-induced obesity and promotes metabolic homeostasis through regulation of fat and muscle metabolism ^[1][2]

Exercise Performance and Muscle Function

• Physical performance enhancement: A single dose of MOTS-c improved running time by 12% and distance by 15% in untrained mice, with benefits observed across young, middle-aged, and elderly animals ^[9][10]
• Exercise-induced expression: Endurance training increases endogenous MOTS-c expression in skeletal muscle and circulation, with levels rising 1.5-5 fold after 4-8 weeks of voluntary exercise ^[9][10]
• Muscle homeostasis: MOTS-c regulates nuclear genes related to metabolism and proteostasis while improving skeletal muscle adaptation to metabolic stress ^[9]

Cardiovascular Health

• Vascular protection: MOTS-c attenuates vascular calcification and secondary myocardial remodeling through AMPK signaling pathway activation ^[8]
• Cardioprotective effects: Lower MOTS-c levels correlate with coronary artery disease severity, suggesting protective effects against atherosclerosis and cardiovascular complications ^[8]

Bone Health

• Osteoporosis prevention: MOTS-c treatment alleviates bone loss by promoting osteoblast differentiation via TGF-β/Smad pathway and inhibiting osteoclast formation through AMPK activation
• Bone formation: Administration increases bone mineral density, bone volume, trabecular number and thickness in ovariectomy-induced osteoporosis models

Aging and Longevity

• Healthspan extension: Late-life intermittent MOTS-c treatment increased physical capacity and healthspan in aged mice ^[9]
• Longevity variants: Genetic polymorphisms in the MOTS-c encoding region (m.1382A>C) specific to Northeast Asian populations may contribute to exceptional longevity ^[7]
• Age-related disease mitigation: MOTS-c shows beneficial effects across multiple age-related conditions including diabetes, cardiovascular disease, and neurodegeneration ^[5][12]

Clinical Safety Profile

MOTS-c has not been clinically tested in humans as a therapeutic peptide, and its safety profile in humans remains unestablished. An analog called CB4211 underwent Phase 1 single and multiple ascending dose trials (NCT03998514) in healthy adults and was found to be safe and well-tolerated after 7 days of dosing, though this analog's safety does not directly translate to MOTS-c itself. Animal studies in mice and rats have demonstrated beneficial effects without apparent toxicity across various disease models, including high-fat diet studies, gestational diabetes, osteoporosis, and aging research. However, the absence of completed human clinical trials means therapeutic safety parameters, optimal dosing, and long-term effects remain unknown.

Regulatory Status

MOTS-c is not approved by the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), or any other regulatory authority for human therapeutic use. The FDA has explicitly ruled that MOTS-c cannot be compounded by pharmacies for human use outside of approved research protocols. The peptide remains classified as an investigational compound available only through research chemical suppliers for laboratory use. MOTS-c is prohibited at all times by the World Anti-Doping Agency (WADA) under Section 4.4.1 as an activator of AMP-activated protein kinase (AMPK), classified as a metabolic modulator on the Prohibited List.

Side Effects and Risks

No significant adverse effects have been reported in preclinical animal studies. Reported side effects in preliminary research are minimal and transient in nature, though comprehensive toxicology data is lacking. The unknown safety profile means potential risks for immune reactions, hormonal disruption, or long-term metabolic effects cannot be ruled out. Drug interactions and contraindications have not been systematically studied.

Research Gaps

Major knowledge gaps include the absence of human pharmacokinetic and pharmacodynamic data, lack of established therapeutic dosing ranges, unknown long-term safety profiles, and no completed efficacy trials in human subjects for any indication. The optimal administration route, frequency, and duration of treatment remain undetermined. Additional research is needed on potential interactions with medications, effects in special populations (pregnant women, children, elderly), and comparative effectiveness versus existing approved therapies.